Petroleo Brasileiro SA Petrobras
PBR
Strategy
MSTR
NVIDIA
NVDA
Vale SA
VALE
KB Home
KBH
US Stock MarketDetailed Quotes
ANRO Alto Neuroscience
- 3.360
- +0.100+3.07%
Close Feb 14 16:00 ET
- 3.360
- 0.0000.00%
Post 17:51 ET
90.62MMarket Cap-1.58P/E (TTM)
3.400High3.210Low178.69KVolume3.260Open3.260Pre Close595.16KTurnover0.92%Turnover RatioLossP/E (Static)26.97MShares18.35052wk High0.55P/B65.19MFloat Cap3.00052wk Low--Dividend TTM19.40MShs Float24.000Historical High--Div YieldTTM5.83%Amplitude3.000Historical Low3.330Avg Price1Lot Size
Trending Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
Alto Neuroscience Stock Forum
Alto Neuroscience Announces Favorable Outcome from Interim Analysis of ALTO-300 Phase 2b Major Depressive Disorder Trial
Wednesday, 12th February at 8:03 am
– Interim analysis resulted in a recommendation to continue the study with a total targeted biomarker population of ~200 patients in the final analysis sample –
– Topline results are expected in mid-2026 –
– The company recently reported an estimated preliminary 2024 year-end cash balance of approximately ...
Clinical Trial Success: Alto's Novel Depression Treatment Hits Key Milestone in Phase 2b Study
Alto Neuroscience Announces Data Presented at the 63rd Annual Meeting of the American College of Neuropsychopharmacology
Wednesday, 11th December at 8:03 am
– Data generated from Alto's precision psychiatry platform and clinical-stage product candidates highlighted across three poster presentations and a panel discussion –
– New preclinical data from a reverse translation study demonstrates the link between the mechanism of ALTO-300 and the EEG biomarker used for...
<- Blackrock ->
$Alto Neuroscience (ANRO.US)$
sec.gov/Archive...
#myANROanalysis
No comment yet